Lates News

Pfizer China announced today that the National Medical Products Administration (NMPA) has officially approved the new generation cAMP-biased GLP-1 receptor agonist exenatide injection (Semglee) for long-term weight management in overweight/obese adults, based on controlling diet and increasing physical activity.